Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Antonio, Texas 78229


The primary objective of this study is to demonstrate that there are no clinically relevant additive inhibitory effects on the HPA-axis when ciclesonide nasal spray is concomitantly administered with orally inhaled HFA-BDP. The secondary objectives are to evaluate safety and tolerability of the combined dosing regimen of orally inhaled HFA-BDP and ciclesonide nasal spray.


Inclusion Criteria: 1. Male or female, 18 - 60 years of age. 2. General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the trial. 3. A history of PAR for a minimum of one year immediately preceding the Screening Visit. 4. A demonstrated sensitivity to at least one allergen known to induce PAR through a standard prick or intradermal test. A positive test is defined as a wheal diameter at least 3 mm larger than the control wheal for the prick test, and 7 mm or greater than the control for the intradermal test. Documentation of a positive result within 12 months prior to the Screening Visit is acceptable. 5. Females of child-bearing potential are currently taking and will continue to use a medically reliable method of contraception for the entire study duration (e.g. oral, injectable, trans-cutaneous or implantable contraceptives or intrauterine devices or double-barrier protection). Women of childbearing potential, or less than 1 year postmenopausal, will require a negative plasma pregnancy test at the Screening Visit as well as at last on-treatment visit. 6. Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and compliance with all study requirements (visits, record keeping, etc). 7. Normal body weight as evidenced by a Body Mass Index (BMI) between ³ 18 and 31 kg/m², and a body weight > 45 kg. Exclusion Criteria: 1. Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the study period. 2. History or physical findings of nasal pathology, including nasal polyps (within the last 60 days) or other clinically significant respiratory tract malformations, recent nasal biopsy (within the last 60 days), nasal trauma, or surgery and atrophic rhinitis or rhinitis medicamentosa (within the last 60 days). 3. Participation in any investigational drug trial within the 30 days preceding the Screening Visit (S0). 4. A known hypersensitivity to any corticosteroid or any of the excipients in the formulations. 5. History or current evidence of clinically relevant allergies or idiosyncrasy to drugs or food. 6. History of alcohol or drug abuse within the preceding two years. 7. History of a positive test for HIV, hepatitis B or hepatitis C. 8. Use of any prohibited concomitant medications within the prescribed (per protocol) withdrawal periods prior to the Screening Visit (S0) and during entire study duration. 9. Previous participation in an intranasal ciclesonide study. 10. Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit (S0). 11. Exposure to corticosteroids for any indication, chronic or intermittent (e.g.: asthma, contact dermatitis), during the past 2 months, or presence of an underlying condition that can reasonably be expected to require treatment with corticosteroids during the course of the study. 12. Use of topical corticosteroids in concentrations in excess of the equivalent of 1% hydrocortisone for dermatological conditions during the past 1 month, or presence of an underlying condition that can reasonably be expected to require treatment with such preparations during the course of the study. 13. Clinically relevant abnormalities in clinical chemical, hematological or any other laboratory variables. 14. Chronic or clinically relevant acute infections. 15. Vegetarian diet or other unusual dietary habits that would preclude the subject's acceptance of standardized meals. 16. Blood donation within the last 30 days before start of the study. 17. Patients that do not have regular sleep patterns (e.g. working at night and sleeping during the daylight hours). 18. Active asthma requiring treatment with inhaled or systemic corticosteroids; intermittent use of beta agonists is acceptable. 19. History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, the common cold, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)] within the 14 days preceding the Screening Visit (S0), or development of a respiratory infection during the Run-in Period. 20. Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit (S0). Low doses of antibiotics taken for prophylaxis are permitted if the therapy was started prior to the Screening Visit (S0) AND is expected to continue throughout the trial. 21. Initiation of immunotherapy during the study period or dose escalation during the study period. However, initiation of immunotherapy 90 days or more prior to the Screening Visit (S0) AND use of a stable (maintenance) dose (30 days or more) may be considered for inclusion. 22. Failure to adequately understand and comply with the HFA-BDP instructions or failure to properly administer study medication.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Becl

Official Title:

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)

Overall Status:


Study Phase:

Phase 3



Minimum Age:

18 Years

Maximum Age:

60 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Intervention Model: Parall

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:AstraZeneca AstraZeneca
Study Director

Study Dates

Start Date:December 2004
Completion Date:December 2005
Completion Type:Actual
Primary Completion Date:April 2005
Primary Completion Type:Actual
Verification Date:October 2016
Last Changed Date:November 30, 2016
First Received Date:April 14, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:24 h plasma cortisol profiles and urinary cortisol
Time Frame:53 days
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:24-hour urinary cortisol will be monitored at the following times
Time Frame:53 days
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Adverse events
Time Frame:53 days
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:vital signs
Time Frame:53 days
Safety Issues:True

Study Interventions

Intervention Type:Drug
Description:Ciclesonide 200µg versus Placebo
Arm Name:1
Intervention Type:Drug
Arm Name:2

Study Arms

Study Arm Type:Active Comparator
Arm Name:1
Description:Ciclesonide 200µg
Study Arm Type:Placebo Comparator
Arm Name:2

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:AstraZeneca

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.